This thesis deals with adaptive enrichment designs, which are especially applied in the development of targeted therapies. These designs are devised for the situation in which a higher treatment effect is assumed in a specific subgroup but efficacy cannot be ruled out in the total population. The idea of this two-stage study design is to decide in an interim analysis based on observed treatment effects whether the subgroup or the total population is selected for enrichment in the second stage of the trial, and for which population a test for efficacy is conducted in the final analysis. The aim of this thesis is to investigate the impact of the interim analysis timing on the power of the study for a normally distributed endpoint. Different...
Based on a Bayesian decision theoretic approach, we optimize frequentist single- and adaptive two-st...
Abstract The development of molecularly targeted therapies for certain types of cancers has led to t...
We propose and evaluate a two-stage, phase 2, adaptive clinical trial design. Its goal is to determi...
Adaptive subgroup enrichment design is an efficient design framework that allows accelerated develop...
Introduction Most literature on optimal group-sequential designs focuses on minimising the expected ...
This dissertation is about two-stage adaptive designs with interim treatment selection. It includes ...
A critical part of clinical trials in drug development is the analysis of treatment efficacy in pati...
The transition towards personalized medicine is happening and the new experimental framework is rais...
This dissertation is about two-stage adaptive designs with interim treatment selection. It includes ...
Methods allowing unplanned adaptations to the sample size based on the interim estimate of treatment...
Methods allowing unplanned adaptations to the sample size based on the interim estimate of treat-men...
Sample size calculations in clinical trials need to be based on profound parameter assumptions. Wron...
We consider the problem of designing a randomized trial for comparing two treatments versus a common...
Adaptive seamless designs combine confirmatory testing, a domain of phase III trials, with features ...
Mid-study design modifications are becoming increasingly accepted in confirmatory clinical trials, s...
Based on a Bayesian decision theoretic approach, we optimize frequentist single- and adaptive two-st...
Abstract The development of molecularly targeted therapies for certain types of cancers has led to t...
We propose and evaluate a two-stage, phase 2, adaptive clinical trial design. Its goal is to determi...
Adaptive subgroup enrichment design is an efficient design framework that allows accelerated develop...
Introduction Most literature on optimal group-sequential designs focuses on minimising the expected ...
This dissertation is about two-stage adaptive designs with interim treatment selection. It includes ...
A critical part of clinical trials in drug development is the analysis of treatment efficacy in pati...
The transition towards personalized medicine is happening and the new experimental framework is rais...
This dissertation is about two-stage adaptive designs with interim treatment selection. It includes ...
Methods allowing unplanned adaptations to the sample size based on the interim estimate of treatment...
Methods allowing unplanned adaptations to the sample size based on the interim estimate of treat-men...
Sample size calculations in clinical trials need to be based on profound parameter assumptions. Wron...
We consider the problem of designing a randomized trial for comparing two treatments versus a common...
Adaptive seamless designs combine confirmatory testing, a domain of phase III trials, with features ...
Mid-study design modifications are becoming increasingly accepted in confirmatory clinical trials, s...
Based on a Bayesian decision theoretic approach, we optimize frequentist single- and adaptive two-st...
Abstract The development of molecularly targeted therapies for certain types of cancers has led to t...
We propose and evaluate a two-stage, phase 2, adaptive clinical trial design. Its goal is to determi...